159 related articles for article (PubMed ID: 37345890)
1. Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases.
Wohlrab J; Kegel T; Große R; Eichner A
J Dtsch Dermatol Ges; 2023 Aug; 21(8):845-851. PubMed ID: 37345890
[TBL] [Abstract][Full Text] [Related]
2. A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis.
Wollenberg A; Thyssen JP; Bieber T; Chan G; Kerkmann U
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2041-2046. PubMed ID: 37319107
[TBL] [Abstract][Full Text] [Related]
3. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.
Solitano V; Facheris P; Petersen M; D'Amico F; Ortoncelli M; Aletaha D; Olivera PA; Bieber T; Ramiro S; Ghosh S; D'Agostino MA; Siegmund B; Chary-Valckenaere I; Hart A; Dagna L; Magro F; Felten R; Kotze PG; Jairath V; Costanzo A; Kristensen LE; Biroulet LP; Danese S
Autoimmun Rev; 2024 Mar; 23(3):103504. PubMed ID: 38128748
[TBL] [Abstract][Full Text] [Related]
4. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
5. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
6. Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis.
Jalles C; Lepelley M; Mouret S; Charles J; Leccia MT; Trabelsi S
Therapie; 2022; 77(6):649-656. PubMed ID: 35710462
[TBL] [Abstract][Full Text] [Related]
7. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
Svoboda SA; Johnson N; Phillips M
Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
[TBL] [Abstract][Full Text] [Related]
8. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Núñez P; Quera R; Yarur AJ
Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
[TBL] [Abstract][Full Text] [Related]
9. [Janus kinase inhibitors for the treatment of atopic dermatitis-evaluation of current data and practical experience].
Lauffer F; Biedermann T
Dermatologie (Heidelb); 2022 Jul; 73(7):520-528. PubMed ID: 35608635
[TBL] [Abstract][Full Text] [Related]
10. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Lefevre PLC; Vande Casteele N
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S725-S736. PubMed ID: 32160283
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
13. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Malato A; Rossi E; Palumbo GA; Guglielmelli P; Pugliese N
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486130
[TBL] [Abstract][Full Text] [Related]
14. Janus Kinase Inhibitors and Non-Melanoma Skin Cancer.
Greif CS; Srivastava D; Nijhawan RI
Curr Treat Options Oncol; 2021 Jan; 22(2):11. PubMed ID: 33423161
[TBL] [Abstract][Full Text] [Related]
15. Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort.
Berthe P; Scailteux LM; Lescoat A; Staumont D; Coiffier G; Guéret P; Dupuy A; Oger E; Droitcourt C
BMJ Open; 2022 Sep; 12(9):e059979. PubMed ID: 36130766
[TBL] [Abstract][Full Text] [Related]
16. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
Xie W; Huang Y; Xiao S; Sun X; Fan Y; Zhang Z
Ann Rheum Dis; 2019 Aug; 78(8):1048-1054. PubMed ID: 31088790
[TBL] [Abstract][Full Text] [Related]
17. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
Misra DP; Pande G; Agarwal V
Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
[TBL] [Abstract][Full Text] [Related]
19. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
20. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
